Stock Events

Stock Events

Autolus Therapeutics 

€1.35
74
-€0.1-6.9% Thursday 19:55

Statistics

Day High
1.47
Day Low
1.27
52W High
2.24
52W Low
1.03
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 6A3A.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Gilead Sciences
GILD
Mkt Cap163.06B
Gilead Sciences, through its acquisition of Kite Pharma, is a leader in CAR-T therapy, making it a direct competitor in the oncology treatment market.
Novartis
NVS
Mkt Cap278.64B
Novartis is a major player in the CAR-T space with approved therapies, competing in the same advanced cancer treatment market as Autolus.
CRISPR Therapeutics
CRSP
Mkt Cap5.29B
CRISPR Therapeutics is involved in gene editing, a technology that can be applied to CAR-T therapy, making it a competitor in the gene therapy market.
Allogene Therapeutics
ALLO
Mkt Cap786.66M
Allogene Therapeutics focuses on allogeneic CAR-T therapies, which are off-the-shelf, directly competing with Autolus' personalized approach.
Precigen
PGEN
Mkt Cap1.5B
Precigen focuses on next-generation gene and cell therapies, including CAR-T, making it a competitor in the advanced therapeutic space.

About

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1; AUTO6NG, a programmed T cell investigational therapy, which is in preclinical trail targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate that is in a Phase I clinical trial for multiple myeloma. It also focuses on developing AUTO5, a hematological product candidate, which is in preclinical development. The company was incorporated in 2014 and is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Christian Martin Itin Ph.D.
Employees
647
Country
United States
ISIN
US05280R1005

Listings

STU
DE
6A3A.STU
MU
DE
6A3A.MU
XNAS
US
AUTL
F
DE
6A3A.F

0 Comments

Share your thoughts

FAQ

What is Autolus Therapeutics stock price today?▼
The current price of 6A3A.STU is €1.35 EUR — it has decreased by -6.9% in the past 24 hours. Watch Autolus Therapeutics stock price performance more closely on the chart.
What is Autolus Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Autolus Therapeutics stocks are traded under the ticker 6A3A.STU.
Is Autolus Therapeutics stock price growing?▼
6A3A.STU stock has risen by +0.75% compared to the previous week, the month change is a +8% rise, over the last year Autolus Therapeutics has showed a +19.47% increase.
How many employees does Autolus Therapeutics have?▼
As of May 15, 2026, the company has 647 employees.
In which sector is Autolus Therapeutics located?▼
Autolus Therapeutics operates in the Health & Wellness sector.
When did Autolus Therapeutics complete a stock split?▼
Autolus Therapeutics has not had any recent stock splits.
Where is Autolus Therapeutics headquartered?▼
Autolus Therapeutics is headquartered in London, United States.